Stockwinners Market Radar for March 29, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:02 EDT Adtran announces retirement of CFO - Adtran "announced that after 39 years in the telecommunications industry, ADTRAN Holdings' CFO, Mike Foliano, will retire from the Company effective on June 28, 2023. The Company also announced the appointment of Uli Dopfer as the Company's new CFO, effective May 1, 2023. Uli Dopfer previously served as CFO of ADVA Optical Networking for the past 8 years."

19:27 EDT Charles Schwab director buys $267.3K in common stock - In a regulatory filing, Charles Schwab disclosed that its director Marianne Brown bought bought 5.0K shares of common stock on March 28th in a total transaction size of $267.3K.

18:38 EDT Wolverine World Wide proposes U.K. workforce reduction - The company states: 'Wolverine World Wide announced actions intended to improve operating performance, fuel global growth, and enable future investments into Sweaty Betty, a global premium women's activewear brand acquired in August 2021. Sweaty Betty will now report into Wolverine Worldwide's London-based International Group, which is responsible for the Company's operations outside the United States. This move will more closely align Sweaty Betty with Wolverine's global centers of excellence. As part of this transition, several opportunities have been identified to better align Sweaty Betty's cost structure to Wolverine's other brands and enable future investments. These include consolidating London office space, securing savings through Wolverine's new Profit Improvement Office, and proposing a UK workforce reduction. The expected impact of these actions is reflected in the Company's 2023 guidance."

18:23 EDT Macy's CEO: We've been working on the CEO transition plan for two years - In an interview on CNBC's Mad Money, Jeff Gennette said Macy's is "ready for me to hand it off." He's "very excited" about Tony Spring's leadership and noted that he's "set to hit the ground running." Gennette added that he's "very committed to ensuring that it's a smooth transition."

18:12 EDT Volta stockholders approve merger transaction with Shell USA - Volta (VLTA) stockholders approved the proposal to adopt the agreement and plan of merger dated January 17 under which Shell USA, a subsidiary of Shell (SHEL), has agreed to acquire Volta through a merger of a direct, wholly-owned subsidiary of Shell USA with and into Volta, with Volta continuing as the surviving corporation in the merger. The transaction is expected to close on or about March 31 subject to customary closing conditions. Following the closing of the transaction, shares of Volta common stock will be delisted from trading on the NYSE and de-registered. Volta stockholders will be entitled to receive $0.86 in cash, without interest and net of withholding taxes, for each share of Volta Class A common stock upon the completion of the merger.

17:47 EDT Stratasys confirms $19.55 per share acquisition proposal from Nano Dimension - Stratasys (SSYS) confirmed that it has received a revised unsolicited non-binding indicative proposal from Nano Dimension (NNDM) to acquire Stratasys for $19.55 per share in cash. Consistent with its fiduciary duties, and in consultation with its independent financial and legal advisors, the Stratasys Board of Directors will carefully review and evaluate the proposal to determine the course of action that it believes is in the best interests of the company and Stratasys shareholders.

17:44 EDT Medical Properties Trust to sell Healthscope portfolio - Medical Properties Trust has entered into a definitive agreement to sell its Australian real estate investments operated by Healthscope to affiliates of HMC Capital, an Australian alternative asset manager focused on real estate strategies, including HealthCo Healthcare & Wellness REIT. The transaction is expected to be completed in the second half of 2023, subject to certain regulatory approvals. Total consideration for the company's Healthscope portfolio is based in part on a lease capitalization rate approximating 5.7%, resulting in anticipated cash proceeds sufficient to fully prepay the AUD$1.2B term loan used to fund the 2019 acquisition of the 11 hospitals leased to Healthscope. At year-end 2022 exchange rates, the term loan was reflected in MPT's financial statements at a U.S. dollar equivalent of approximately $818M; at the same exchange rate, 2023 annualized GAAP rent would be approximately $54M.

17:41 EDT National CineMedia to delay filing 10K, in talks with lenders - In a regulatory NT 10-K filing the company states: "National CineMedia and its subsidiary, National CineMedia, LLC, together with professional advisors, are actively engaged in negotiations with certain lenders of NCM LLC. As a result of the time needed to finalize our ongoing discussions with NCM LLC's lenders and the material impact that these discussions will have on the Company's disclosures in its Annual Report on Form 10-K for the year ended December 29, 2022, the financial reporting process could not be completed without unreasonable effort prior to the Form 10-K's original due date. We have therefore filed this notification form to provide us with additional time to complete the preparation of the Company's Form 10-K."

17:33 EDT Seelos Therapeutics pauses additional patient enrollment in SLS-005-302 study - Seelos Therapeutics "announced a business update on its key programs. In order to focus the majority of its resources on the ongoing registration directed study of SLS-002 for Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder and the fully enrolled phase II/III study of SLS-005 in amyotrophic lateral sclerosis, Seelos is temporarily pausing additional enrollment of patients in the SLS-005-302 study in spinocerebellar ataxia type 3. Patients already enrolled will continue in the study and data will continue to be collected in order to make decisions for resuming enrollment in the future. This temporary pause has been implemented as a business decision due to financial considerations, and is not based on any data related to safety or therapeutic effects."

17:28 EDT Lockheed Martin awarded $120.27M Navy contract modification - Lockheed Martin was awarded a $120.27M cost-plus-incentive-fee modification to a previously awarded contract. This modification exercises an option to provide continued engineering, maintenance, logistics, and material support in support of the development, production, and sustainment of software builds, as well as to execute developmental flight tests in support of the F-35 Joint Strike Fighter aircraft for the Air Force, Marine Corps, Navy, and Foreign Military Sales and non-U.S. Department of Defense, or DOD, partners. Work is expected to be completed in March 2024. The Naval Air Systems Command is the contracting activity.

17:22 EDT Raytheon Technologies awarded $619.24M Navy contract modification - Raytheon was awarded a $619.24M fixed-price incentive modification to previously awarded contract to exercise options for hardware production of the AN/SPY-6(V) family of radars. Work is expected to be completed by September 2026. FY23 shipbuilding and conversion funds in the amount of $470.62M and FY23 other procurement funds in the amount of $148.62M will be obligated at the time of award and will not expire at the end of the current fiscal year. The Naval Sea Systems Command is the contracting activity.

17:18 EDT Crane to replace PacWest Bancorp in S&P 400 at open on 4/4

17:08 EDT mCloud retains ATB Capital Markets, Maxim to explore strategic alternatives - mCloud Technologies "announced it has formed a special committee comprising independent members of mCloud's Board of Directors that has retained ATB Capital Markets Inc. and Maxim Group LLC as financial advisors for the purpose of exploring currently active strategic alternatives. ATB and Maxim will assist the Special Committee in evaluating potential private and public structure alternatives that are being explored to determine the most viable outcomes maximizing value for the Company's securityholders."

17:03 EDT Peabody Energy falls 3% to $24.40 after confirming fire incident at Shoal Creek

17:01 EDT Semantix increases stock repurchase plan by $5M - Semantix has authorized an increase in the company's existing stock repurchase plan approved by the Board in November 2022 from up to $5M to a total of up to $10M.

16:50 EDT View Inc. to cut about 170 jobs - In a regulatory filing, the company states: "On March 27, 2023, the Board of Directors of the Company approved a restructuring plan to reduce structural costs, including with respect to the Company's workforce. Pursuant to the Plan, the Company expects to decrease overall headcount by approximately 170 employees, which represents approximately 23% of full-time employees as of March 28, 2023. The reduction in workforce is expected to be substantially implemented in March 2023. The implementation of the Plan is expected to reduce expenses by approximately $23 million over the next 12 months. All employees affected by the reduction in workforce will be eligible to receive, among other things, severance payments based on the applicable employee's level at the Company and the continuation of benefits for a specified time period post-termination. Each affected employee's eligibility for severance benefits is contingent upon such employee's execution of a separation agreement, which includes a general release of claims against the Company. The Company expects to incur a one-time charge of approximately $5 million in the first quarter of 2023 related to the Plan, consisting primarily of one-time severance payments upon termination of the employees impacted by the reduction in workforce and continued benefits for a specific period of time with related cash payments expected to be substantially paid out by April 30, 2023. The Company expects such payments to be the only direct expense of the Plan. The Company does not expect to recognize a stock-based compensation expense for impacted employees related to vested awards and does not anticipate modifying the affected employees' stock awards in a manner that would result in additional expenses."

16:45 EDT Highland Capital Management buys $1.3M in Paratek Pharmaceuticals shares - In a regulatory filing, Paratek Pharmaceuticals disclosed that James Dondero of Highland Capital Management bought 788.5K shares of common stock on March 17th in a total transaction size of $1.3M.

16:45 EDT Sonoco teams with GreenGasUSA to reduce emissions and provide renewable energy - Sonoco has upgraded its Hartsville wastewater treatment site to significantly reduce carbon emissions. The company began treating wastewater from its paper operations in the 1950's and in 1987, an anaerobic lagoon was added to improve the system's efficiency. Anaerobic wastewater treatment is a highly efficient treatment process that uses less energy and produces less sludge than conventional aerobic treatment. The organic matter in the wastewater is converted to carbon dioxide and methane. In addition to the anaerobic treatment, a cover on the lagoon had been capturing the gases and routing them to a flare for destruction. In partnership with renewable natural gas developer GreenGasUSA, new biogas equipment now converts any gaseous methane to pipeline quality renewable natural gas for use in homes and businesses using the existing interstate pipeline system. It's expected to reduce Sonoco's greenhouse gas emissions by 8,000 metric tons per year and provide renewable energy to South Carolina. "We're proud of our sustainability record in Hartsville and our history of doing the right thing for the environment," said Sonoco Vice President of Environmental, Sustainability, & Technical Services Elizabeth Rhue."This GreenGasUSA partnership allows us to take our efforts one step further by turning a waste gas into a valuable resource for the community while reducing our carbon footprint," said Rhue. "We see this investment as a win for Sonoco, a win for GreenGas, and, most importantly, a win for the environment."

16:40 EDT Concentrix trading resumes

16:30 EDT Granite awarded $20M contract by Alaska Department of Transportation - Granite has been awarded an approximately $20M contract by the Alaska Department of Transportation to rehabilitate a 10-mile section of Richardson Highway north of Glennallen, AK. The project will be funded by the Federal Highway Administration and will be included in Granite's 2023 first-quarter CAP.

16:28 EDT Concentrix to acquire Webhelp in $4.8B transaction - Concentrix announced they have entered into an agreement to combine with Webhelp in a transaction valued at approximately $4.8B, including net debt. Webhelp specializes in CX, sales, marketing, and payment services with a client and delivery footprint in Europe, Latin America, and Africa. Chris Caldwell, president and CEO of Concentrix, will lead the combined organization. Concentrix has entered into a binding put option agreement to combine with Webhelp. Upon completion of customary works council consultations, the parties will enter into a definitive purchase agreement. Under the terms of the agreement, Concentrix will acquire 100% of the shares of Webhelp. Shareholders of Webhelp will receive 14.9M shares of Concentrix, EUR 500M of cash proceeds, and a EUR 700M note payable in two years, bearing an interest rate of 2%, with the right to earn an additional 0.75M shares of Concentrix if the Concentrix share price reaches $170.00 per share within seven years from the closing of the transaction. Additionally, Webhelp's targeted net debt of approximately EUR 1.55B will be refinanced when the transaction closes. Upon closing of the transaction, Concentrix shareholders will own approximately 78% of the combined company with Webhelp shareholders owning approximately 22%. Maintaining its commitment to a diverse board of directors, the combined company will have a ten-member board, including two new board members that are expected to be Olivier Duha as Vice Chair of the Board and Nicolas Gheysens, as a representative of GBL. Cost synergy benefits are expected to be $75M in the first full year after closing, achieving a minimum of $120M, net of investments, by the third full year. At close, Concentrix is expected to have approximately $5.1B of total debt outstanding, consisting of newly issued senior notes, the EUR 700M note payable, and its existing credit and accounts receivable securitization facilities. Based on estimated pro forma adjusted EBITDA of approximately $1.6B in 2023 and expected net debt of approximately $4.9B at close, net debt-to-adjusted EBITDA is expected to be approximately 3x at transaction close and is expected to decrease to close to 2x within two years. Total transaction value of $4.8B and expected 2023 Webhelp revenue and adjusted EBITDA are based on an assumed exchange rate of 1.08 USD/EUR. The transaction value also reflects a Concentrix share price of $120.00 per share. The transaction is expected to close by the end of the year, subject to customary closing conditions, including approval by Concentrix shareholders and regulatory approvals. Certain shareholders of the company, including MiTAC International Corporation, which collectively owned approximately 15% of Concentrix common stock as of March 29, have agreed to vote their shares in favor of the transaction. Until the transaction is completed, the companies will continue to operate independently.

16:21 EDT Atreca: Phase 2 go/no-go decisions for ATRC-101 expected by end-of-year - Atreca is continuing to enroll subjects in both the Q3W monotherapy and combination therapy cohorts at the 30 mg/kg dose level, with a focus on the recruitment of H-score high participants across tumor types. Additional data from the ongoing study will inform a future decision concerning whether to advance ATRC-101 into Phase 2 studies and in which indications. Atreca expects to report additional data from the Phase 1b study and provide details on its potential Phase 2 development plans by the end of 2023. "These results are encouraging and reinforce our belief in the therapeutic potential of ATRC-101. Importantly, they support the relationship we've observed between target expression and both ATRC-101's anti-tumor activity and duration of response," added Dr. Philippe Bishop, Chief Medical Officer of Atreca. "We look forward to providing a development update with go/no-go decisions later this year."

16:20 EDT Peabody Energy trading resumes

16:16 EDT McDonald's: Robert Eckert and John Rogers, Jr. to retire from board - McDonald's announced the retirement of Robert Eckert and John Rogers, Jr. from the McDonald's Board of Directors effective as of the date of the company's 2023 Annual Shareholders' Meeting. These retirements are consistent with the Board's commitment to ongoing refreshment that maintains an appropriate balance of continuity and institutional knowledge with fresh perspectives among Directors. In 2022, the Board elected four new independent Directors and announced one retirement.

16:14 EDT Planet Labs to acquire Sinergise - Planet Labs "announced it has signed an agreement to acquire the business of Holding Sinergise d.o.o., a leading developer platform for earth observation data. Planet expects this acquisition to lower the barriers for current and new Planet customers to access and act on EO data. The addition of Sinergise's platform capabilities is expected to further enable customers to more easily extract insights from various sources of satellite data and partners to build their own applications on top of Planet's platform to gain additional value from EO data. The transaction is expected to close during Q2 of Planet's current fiscal year and is subject to certain closing conditions."

16:11 EDT RH down 4% after earnings, guidance - Shares of RH are down $10.20, or 4%, to $235.55 in after-hours trading.

16:11 EDT Evolent Health, Centene expand partnership - Evolent Health (EVH) announced an agreement to expand its Technology and Services solution for oncology with its existing partner, Centene (CNC). Centene will expand its use of Evolent Health's oncology solution across its Centene and WellCare Medicare Advantage members nationally. This agreement deepens the specialty care partnership between Centene and Evolent in the MA market.

16:10 EDT Concentrix trading halted, news pending

16:07 EDT Akero Therapeutics provides details for upcoming SYNCHRONY program - Akero Therapeutics announced an End-of-Phase 2 meeting with the FDA as well as details of the anticipated SYNCHRONY Phase 3 efruxifermin program for the treatment of nonalcoholic steatohepatitis, or NASH. There are currently no approved therapies for the treatment of NASH, a serious form of liver disease estimated to affect more than 17M Americans. Based on ongoing discussions with the FDA, the SYNCHRONY Phase 3 program will start enrolling patients into two parallel, randomized, placebo-controlled clinical trials during the second half of this year. SYNCHRONY Histology will evaluate the efficacy of 28mg and 50mg doses of EFX in patients with biopsy confirmed pre-cirrhotic NASH, with fibrosis stage 2 or 3. The primary endpoint will be greater than or equal to 1-stage fibrosis improvement and resolution of NASH. SYNCHRONY Real-World will assess safety and tolerability of EFX in patients with non-invasively diagnosed NASH or NAFLD. Key secondary endpoints are to include change in biomarkers of fibrosis and other established non-invasive endpoints. The duration of and total number of subjects to be enrolled in the SYNCHRONY Histology and Real-World trials are subject to confirmation with the FDA. Following readout of the Phase 2b SYMMETRY trial during the fourth quarter of this year, and subsequent interactions with the FDA, Akero expects to finalize the design of the third Phase 3 clinical trial within the SYNCHRONY program. SYNCHRONY Outcomes is planned to evaluate the efficacy and safety of EFX in a compensated cirrhotic population, for which the primary endpoint will be clinical outcomes.

16:04 EDT Arcellx reports Q4 net loss $39.0M vs. $20.7M last year - Arcellx expects that the cash on hand will fund its operations through BLA filing of CART-ddBCMA planned for the first half of 2025. "2022 was a stellar year for Arcellx, both from a business and clinical perspective. We completed a successful IPO in February, secured additional capital through a follow-on offering in June, and ended the year announcing a global partnership with Kite to co-develop and co-commercialize CART-ddBCMA in multiple myeloma. In parallel, we initiated two Phase 1 studies utilizing our dosable and controllable CAR-T technology, ARC-SparX, and our Phase 2 iMMagine-1 pivotal study and presented robust long-term data from our Phase 1 expansion study of CART-ddBCMA in multiple myeloma at ASCO and ASH. We also made significant progress on the manufacturing front, setting us up for scalable manufacturing in the future," said CEO Rami Elghandour. "Leveraging our balance sheet of $580 million positions us to continue building on our strong foundation as we advance our pipeline programs. Our team, in collaboration with our colleagues at Kite, remains focused on completing enrollment of iMMagine-1, initiating iMMagine-2 in earlier multiple myeloma lines, and presenting longer-term data from our Phase 1 expansion study of CART-ddBCMA. We're also beginning commercial planning as we prepare for U.S. market entry with the goal of meeting the demand of the many patients in need."

15:07 EDT Petrobras trading resumes

14:56 EDT Petrobras says investment, divestment review must be carried out based on plan - In a regulatory filing, Petrobras "informs that its Board of Directors has considered, on today's date, the content of Official Letter 166/2023/GM-MME, of 02/28/2023, and of Official Letter 257/2023/GM-MME, of 03/29/2023, and considering its attributions, concluded that the review of the investment and divestment processes must be carried out based on the company's 'Strategic Plan,' prepared by the Executive Board and approved by this Board, pursuant to Petrobras' Bylaws. Therefore, in view of the Ministry of Mines and Energy's request and the election of the new Executive Board on 03/29/2023, the Board of Directors will study the matter, in case the new management, which has just taken office, decides to propose the revision of the 'Strategic Plan.' It is worth noting that this revision should not include divestments already in the phase of signing and closing contracts in order to fully comply with the rights and obligations already assumed by the Company, with schedules and dates already set to occur throughout the four quarters of 2023, and thus not cause any damage to the parties involved in the negotiations, especially Petrobras. Material facts will be timely disclosed to the market." Reference Link

14:51 EDT Genius Group CEO says sent Troika Media non-binding acquisition offer - Roger James Hamilton, CEO of Genius Group (GNS), tweeted: "Also Genius Group $GNS has sent to Troika Media a non-binding offer to acquire $TRKA together with a proposal on capital restructure. As agreed with @Jefferies terms are confidential. Offer approved by $GNS Board. Proceeding subject to $TRKA go-ahead (or not) [...] An offer isn't any guarantee acquisition will occur as acceptance, DD, approvals, etc are all required. Also $TRKA is one of multiple companies $GNS is in discussion with. However in 2023 we arr committed to an M&A strategy to get to critical mass to fight #NakedShorts" Reference Link

13:38 EDT Clearlake 'disappointed' with Blackbaud Board's rejection, reiterates offer - Clearlake Capital has submitted a letter to the Blackbaud Board of Directors, in response to its rejection of Clearlake's offer to acquire Blackbaud for $71.00 per share on March 27, 2023. In the letter, Clearlake said that, "We have reviewed the Company's response to our March 24, 2023 acquisition proposal via the press release issued publicly by the Company and related response letter, both dated March 27, 2023. We are disappointed that the Board has rejected our highly attractive acquisition proposal of $71.00 per share... Many enterprise software companies have a challenging path forward in the current environment, and we believe the Company's current challenges would be best addressed by exploring strategic alternatives via a formal process to maximize stockholder value... We were surprised that one of the stated reasons conveyed to us for the Board's rejection of our proposal was that it 'lacks critical details typically included in a credible proposal.' Neither the Board nor its advisors sought to engage with us at any point to clarify any details of our proposal that the Board deemed to be lacking, or ask us any questions about our proposal... We also note that our 'unambiguous statement that Clearlake does not need to be an acquirer' was made in recognition of the fiduciary duties of the Board under the Revlon doctrine as part of a strategic process, especially since we believe the Company has recently rejected other credible third-party acquisition overtures. Our statement should not otherwise be mischaracterized... We hereby reiterate our all-cash offer to acquire the outstanding shares of the Company for $71.00 per share, as outlined in our March 24th proposal. Based on public information and the Company's unaffected price, we believe that our proposal will deliver superior and certain value to all stockholders when compared to the standalone alternative and will be very compelling to the Company's stockholders."

13:01 EDT Apple WWDC to run from June 5-9 - Apple stated in a post to its Developer site: "Mark your calendars June 5 through 9 for an exhilarating week of technology and community. Be among the first to learn the latest about Apple platforms, technologies, and tools. You'll also have the opportunity to engage with Apple experts and other developers. All online and at no cost. In addition, Apple will host a special all-day event for developers and students on June 5 at Apple Park. Watch the keynote and State of the Union videos together, meet some of the teams at Apple, celebrate great apps at the Apple Design Awards ceremony, and enjoy activities into the evening." Reference Link

12:05 EDT Verint announces expanded partnership with Google Cloud - Verint (VRNT) announced an expanded partnership with Google Cloud (GOOG, GOOGL) to help organizations improve contact center performance through the integration of Google Cloud's Contact Center AI and Verint Customer Engagement Platform.

12:00 EDT Direxion Daily Semiconductor Bear 3X Shares falls -6.7% - Direxion Daily Semiconductor Bear 3X Shares is down -6.7%, or -$1.29 to $18.03.

12:00 EDT Stem falls -13.7% - Stem is down -13.7%, or -85c to $5.38.

12:00 EDT Gatos Silver rises 10.6% - Gatos Silver is up 10.6%, or 54c to $5.62.

11:28 EDT CompoSecure announces extension of American Express contract - CompoSecure (CMPO) announced that it has extended its 20-year contract with American Express (AXP) as a provider of premium metal payment cards through July 2026. Jon Wilk, President and CEO of CompoSecure said that, "American Express is a leader in delivering innovative products and services, always with a focus towards providing an exceptional customer experience. We are thrilled to continue our relationship together."

11:22 EDT Conn's CEO says total retail sales down 18.6% in Q1-to-date - Conn's CEO Norman Miller said during the company's Q4 earnings call, according to a transcript: "Finally, given the uncertain economic environment and in lieu of official guidance, I want to provide some details on recent sales trends and considerations for the year. Since the third quarter, sales trends have improved or remained stable as we have refocused the business on our core credit-constrained consumer. These trends continued into the first quarter with total retail sales down 18.6% quarter-to-date. Looking forward through the remainder of the fiscal year, we expect retail sales to improve on a sequential basis as we benefit from the growth strategies we have discussed today."

10:55 EDT SEC charges crypto trading platform Beaxy for operating unregistered exchange - The Securities and Exchange Commission charged the crypto asset trading platform beaxy.com and its executives for failing to register as a national securities exchange, broker, and clearing agency. The SEC also charged the founder of the platform, Artak Hamazaspyan, and a company he controlled, Beaxy Digital, Ltd., with raising $8M in an unregistered offering of the Beaxy token and alleged that Hamazaspyan misappropriated at least $900,000 for personal use, including gambling. Finally, the SEC charged market makers operating on the Beaxy Platform as unregistered dealers. According to the SEC's complaint, since October 2019, Nicholas Murphy and Randolph Bay Abbott, through the company they managed, Windy Inc., maintained and provided the Beaxy Platform as a web-based trading platform that facilitated buying and selling of crypto assets that were offered and sold as securities. The complaint alleges that Windy, through the Beaxy Platform, violated the Securities Exchange Act of 1934 because it: Brought together the orders for securities of multiple buyers and sellers using established, non-discretionary methods under which such orders interacted, and the buyers and sellers entering such orders agreed to the terms of a trade, and thus should have registered as an exchange; Acted as an intermediary in making payments and deliveries upon matching sell and buy orders and maintained custody of customer assets, and thus should have registered as a clearing agency; and Was regularly engaged in the business of effecting transactions for the account of others in crypto assets that were offered and sold as securities, and thus should have registered as a broker. Reference Link

10:35 EDT AMGUARD enters supply agreement with NewLeaf Symbiotics - AMGUARD Environmental Technologies entered into a supply agreement with NewLeaf Symbiotics to bring biological solutions to major North American specialty markets. Under the agreement, AMGUARD becomes the exclusive seller of NewLeaf products including bio-stimulants and bio-protection products in golf, ornamental, controlled-environment agriculture, cannabis, and consumer markets in the U.S., Canada, and Mexico. Together these production areas are estimated to comprise slightly more than 50 million treatable acres in North America.

10:00 EDT ReneSola falls -6.0% - ReneSola is down -6.0%, or -25c to $3.93.

10:00 EDT Stem falls -18.5% - Stem is down -18.5%, or -$1.16 to $5.08.

10:00 EDT Natural Gas Services rises 11.5% - Natural Gas Services is up 11.5%, or $1.16 to $11.28.

09:56 EDT Ambit Biosciences Corp trading resumes

09:52 EDT Coeptis Therapeutics obtains exclusive rights to negotiate to acquire VyGen-Bio - Coeptis Therapeutics has obtained the exclusive right to negotiate towards the acquisition of VyGen-Bio, Inc. or its assets. Coeptis intends to immediately commence its due diligence review of VyGen-Bio's assets, including its IP and knowhow related to rights to GEAR cell therapy and companion diagnostic platforms, and, depending on the results of its due diligence analysis, turn to negotiation of definitive deal documents. VyGen-Bio's product candidates and platforms were discovered by scientists at the world-renowned Karolinska Institutet in Stockholm, Sweden, including Dr. Arnika Wagner, who is expected to play a key collaborative development role for Coeptis as the Company builds its capabilities to develop treatments for cancer and gains technologies to develop additional cell and gene therapies. This transaction, if finalized, would expand upon Coeptis' collaboration with VyGen-Bio, which is currently focused on CD38-GEAR-NK, a natural killer cell therapy for the treatment of CD38+ cancers with an initial focus on multiple myeloma, and CD38-Diagnostic, an in vitro diagnostic tool being developed to help identify cancer patients who may be appropriate candidates for anti-CD38 mAb therapy. In the event a transaction is consummated, Coeptis would then be in a position to advance the development of various GEAR-engineered cells, including NK cells, T cells, and hematopoietic stem cells, and to pursue development of GEAR-engineered cells for use in combination with mAbs that target a potentially wide range of receptor targets. Additional development options that would be explored could include therapeutic modalities where the antigen-specificity of mAbs is used, such as CAR-T and bispecific antibodies for the treatment of a broad range of hematologic malignancies and solid tumors.

09:50 EDT Emergent BioSolutions: FDA approves OTC designation for Narcan Nasal Spray - Emergent BioSolutions announced that the U.S. FDA has approved Narcan Naloxone HCl Nasal Spray 4 mg as an over-the-counter emergency treatment of opioid overdose. This decision comes at a time when approximately every eight minutes, a person dies from an opioid overdose and research shows the epidemic is escalating in the U.S. with the rise in synthetic opioids. By offering Narcan Nasal Spray as an OTC treatment, anyone will be able to access it without a prescription, which is an important step in the fight to reduce the number of opioid overdose deaths occurring each day.

09:47 EDT ReneSola falls -6.5% - ReneSola is down -6.5%, or -27c to $3.91.

09:47 EDT Natural Gas Services rises 11.5% - Natural Gas Services is up 11.5%, or $1.16 to $11.28.

09:47 EDT Emergent BioSolutions rises 17.5% - Emergent BioSolutions is up 17.5%, or $1.56 to $10.46.

09:38 EDT Knightscope announces contract renewal from hospital for K5 ASR - Knightscope announces that a long-time healthcare client has renewed its K5 Autonomous Security Robot contract for the seventh consecutive year.

09:34 EDT United States Luggage Company partners with JetBlue Travel Products - United States Luggage Company announced a partnership with JetBlue Travel Products. Customers can now purchase travel bags from Briggs & Riley and Solo on Paisly.com, JetBlue Travel Products' homegrown travel booking website, and earn Mosaic-qualifying TrueBlue points along the way. By purchasing a travel bag on Paisly.com, customers will also have access to a 24/7 dedicated phone line to Paisly's helpful humans, should they want to repair or replace their travel bag, plus free shipping and returns on all purchases.

09:32 EDT Wendy's, DoorDash partner for 'Biggie' Power Hours - The companies said, "Wendy's (WEN) and DoorDash (DASH) are ending March the only way we know how - with a BIGGIE deal. That's right, it's time for the biggie-st deal in basketball ahead of the last weekend of biggie games, biggie buckets and biggie wins. It's time for DoorDash and Wendy's Biggie Power Hours. 'Biggie' Power Hours: To properly tip-off the biggie-st weekend in basketball, Wendy's and DoorDash are calling 'Biggie' Power Hours from 6:00 - 7:00 PM EDT on both Thursday, March 30 and Friday, March 31. Planned for one full hour each day across the country, when fans order a Biggie Bag via DoorDash using the promo code BIGGIE and spend at least $12, they'll receive up to $30 off their entire order. Talk about the ultimate pregame to the weekend!"

09:27 EDT Rumble offers 100% creator revenue share for subscription badges until year-end - Rumble announced that creators will receive additional monetization opportunities through the end of 2023. For the rest of the year, creators will receive 100 percent of the revenue from the purchase of monthly subscription badges, which Rumble recently launched for the price of $5 per month.

09:19 EDT Smith Micro provides update on workforce reductions, closes Slovakian operations - Smith Micro provided an update to its previously announced cost reduction initiatives. In furtherance of these initiatives, the company earlier this month executed workforce reductions in the United States and Portugal and announced the further reduction of its global workforce in Serbia and Slovakia. In the aggregate, these actions will result in a reduction of approximately 26% of the company's total global workforce. Along with these actions, the company announced its decision to close its Slovakian operations, effective June 30, 2023. In addition, the company has reduced the base salaries of its executive team and the fees paid to its board of directors and suspended its quarterly bonus program, in all cases until the Company returns to profitability on a non-GAAP basis, including the effects of the restored salaries, board fees and bonus program. The Company has also continued its ongoing optimization initiatives related to third-party costs, as its efforts to migrate family safety customers to the company's SafePath platform near completion.

09:17 EDT AAR Corp. to acquire nine Boeing 757-200 passenger aircraft - AAR CORP. announced its subsidiary AAR Supply Chain will acquire nine Boeing 757-200 passenger aircraft equipped with 18 Rolls-Royce RB211 engines from American Airlines. The assets have been most recently operated by American Airlines.

09:15 EDT Arcturus Therapeutics says cash runway now extends to 2026 - In its Q4 results last night, Arcturus Therapeutics stated: "The Company's cash balance totaled $391.9 million at December 31, 2022, compared to a cash balance of $370.5 million at December 31, 2021. In March 2023, the Company repaid Singapore $17.1 million which triggered the elimination of $33.3 million in non-recourse debt pertaining to the ARCT-021 program." Andrew Sassine, CFO of Arcturus Therapeutics, also noted: "Within the first four months of our CSL collaboration, we successfully achieved multiple program objectives, triggering $90 million in milestone payments. Additionally, with the elimination of $33.3 million of non-recourse debt to Singapore, our cash runway now extends into the beginning of 2026."

09:12 EDT Nikola, Klean Industries partner to convert truck fleets to FCEVs - Klean Industries has executed a Memorandum of Understanding with Nikola Corporation.The companies intend to collaborate and encourage the adoption of Nikola Class 8 zero-emission vehicles with Klean's partners, and feedstock suppliers while developing green hydrogen supply and dispensing infrastructure in the United States and Canada. Nikola will evaluate offtake opportunities from green hydrogen projects being developed by Klean and its partners involving hydroelectric, wind, and solar power in the Pacific Northwest and Canada. Utilizing Klean's green hydrogen, the companies will also work together to convert Klean's logistics partners' truck fleets to Nikola Class 8 zero-emission vehicles.

09:10 EDT Mayfair Gold announces latest set of drill results from Fenn-Gib - Mayfair Gold announces the latest set of drill results from the Fenn-Gib resource expansion and infill drill program. Mayfair's 100% controlled Fenn-Gib Project, located in the Timmins region of Northeast Ontario, hosts a NI 43-101 open-pit constrained Indicated Resource of 3.06 million ounces and an Inferred Resource of 0.31M ounces, with disseminated gold mineralization striking east-west on the Pipestone Fault over more than 1.25 kilometers and up to 300 meters wide at the west end. "The size and quality of the Fenn-Gib deposit is evident from the wide areas of higher-grade gold mineralization we continue to define both within and below the current conceptual open pit," said Mayfair Gold President and CEO Patrick Evans. "Gold mineralization has been intercepted in every hole drilled over the past 27 months; however, it is apparent from some of the lower-grade intercepts reported today that we are approaching the outer limits of the Fenn-Gib mineralization. Based on assay results received to date, Mayfair is planning to release an updated NI 43-101 resource statement in the second quarter."

09:08 EDT GrowLife's Bridgetown Mushrooms formally enters mycology business - GrowLife, the owner of Bridgetown Mushrooms, has formally entered the fast-growing Mycology business with a complete suite of products tailored to meet the demands of commercial mushroom farmers across the country. Dave Dohrmann, Chairman and CEO of GrowLife, commented, "This past February, Bridgetown answered years of requests from commercial farmers and soft launched our long-coveted proprietary substrate and soil mix, along with a complete suite of Mycology supplies. We began delivering product to Portland-area commercial farmers in early March. Now, we're ready to scale and meet the tremendous demand for our suite of Mycology products across the country. As a result of coming out of the gate this strong, we expect our Mycology division to have a positive material impact on our financial results going forward."

09:07 EDT Wyndham Hotels & Resorts becomes official hotel partner of Minor League Baseball - Wyndham Hotels & Resorts announced a new multi-season partnership with Minor League Baseball. The deal makes Wyndham the Official Hotel Partner of Minor League Baseball with its award-winning loyalty program, Wyndham Rewards, becoming MiLB's Official Hotel Loyalty Partner. Through Wyndham's new relationship with Minor League Baseball, Wyndham Rewards members will soon be able to redeem points for access to all that MiLB has to offer, including: tickets to Minor League games, experiences such as throwing a first pitch, behind-the-scenes ballpark tours, batting practice field access and more. Benefits are slated to go live later this summer. Wyndham's partnership with Minor League Baseball also includes branded stadium features, sponsorship of Minor League Baseball's Official Ballpark Guides, a social and digital media presence, and Wyndham booking links on MiLB.com as well as all 120 Minor League Baseball Club sites.

09:06 EDT Skyhawk Security uses ChatGPT to enhance cloud threat detection - Skyhawk Security announced the company is using ChatGPT to enhance cloud threat detection and make it faster and easier for customers to find and understand security incidents that might otherwise fly under the radar. Tests run by Skyhawk on the new ChatGPT features showed measurable improvements in the speed of detecting breaches based on anomalous activities, doing so at a much lower operational cost. According to Skyhawk's tests on various datasets, in 78% of cases the platform produced alerts earlier when adding ChatGPT to the scoring process. This capability is generally available to Skyhawk customers today at no additional charge.

09:06 EDT Lucy Scientific Discovery appoints Kash Heed as Specific Advisory - Lucy Scientific Discovery announced that former British Columbia Solicitor General Kash Heed has joined the company as a Special Advisor. Among other important contributions, Heed will apply his knowledge from decades of public service to help the company successfully navigate Canada's rapidly evolving drug policy landscape and growing budget focused on mental health and safe-supply programs.

09:05 EDT Canadian Net REIT CEO Jason Parravano resigns, Kevin Henley to succeed - Canadian Net Real Estate Investment Trust announced that they have accepted the resignation of its President, CEO and Trustee, Jason Parravano. After 8 successful years with the Trust, Mr. Parravano will be stepping down from his position on April 25th, 2023. At that time, Kevin Henley, Chief Investment Officer, will assume the role of President and CEO.

09:03 EDT LPL Financial: Kemp Cunningham joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisor Kemp Cunningham CFP, MBA has joined LPL Financial's broker-dealer, RIA and custodial platforms. He reported having served approximately $125 million in advisory, brokerage and retirement plan assets, and joins LPL from Edward Jones.

09:02 EDT Brera Holdings to announce host city for FENIX Trophy 'Final Four' - The FENIX Trophy, called the "Champions League for Amateurs" by BBC Sport, created, owned and promoted by Brera Holdings and recognized by UEFA, has set its field of teams and will shortly announce the host city for its "Final Four" stage taking place in June 2023. The FENIX Trophy tournament in 2023, which is the second annual tournament, will bring together 9 non-professional European football clubs, chosen for their exceptional social, historical and cultural distinctiveness, including clubs rebuilt and run by their fans, clubs featuring significant social and cultural projects, and clubs with extraordinary communication skills. In line with its motto "Making friends, not millionaires," the FENIX TROPHY in just two years of existence has emerged as a European network of cult non-professional clubs.

09:00 EDT Sabre and American Airlines to go live with NDC content - Sabre (SABR) and American Airlines (AAL) announced the availability of American's NDC offers through Sabre's global distribution system. Starting on April 3, Sabre-connected travel buyers, agencies and developer partners will be able to shop, book, and service American's NDC content, including paid seats, through Sabre's Offer and Order APIs, the agency point-of-sale tool, Sabre Red 360, and the online booking tool, GetThere. Travel buyers connected to the Sabre GDS will be able to choose enhanced offers from American such as the Main Select and Flagship Business Plus fares, ancillary products and the lowest fares available in these channels. They will also have access to more descriptive information on American's flight offers as well as seat selection enabled in the booking path.

08:56 EDT Bioventus reschedules reporting of Q4, 2022 results - Bioventus announced that it will now report financial results for the fourth quarter of fiscal year 2022 before the market opens on Friday, March 31, 2023, rather than as previously announced to allow additional time to complete its financial statements. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

08:55 EDT Gain Therapeutics presents preclinical data from GBA1 Program - Gain Therapeutics announced the presentation of new pre-clinical data supporting the potential of its structurally targeted allosteric regulators of glucocerebrosidase to prevent neurodegeneration in Alzheimer's disease. The data will be shown in a poster presentation at the 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders being held March 28 - April 1, 2023 in Gothenburg, Sweden. The data generated in two cell-based assays of Alzheimer's disease showed that Gain's orally bioavailable, brain-penetrant structurally targeted allosteric regulators of GCase show promising activity against Amyloid Beta 1-42 and oligomeric Tau toxicity, which are thought to underlie neurodegeneration and cognitive impairment in Alzheimer's disease. The neuroprotective properties of STAR compounds were evaluated in cellular models of AD with primary rat cortical and hippocampal neurons challenged with Abeta-1-42 and human Tau oligomers, respectively. The data presented in the poster titled "Small-Molecule Structurally Targeted Allosteric Regulators of Glucocerebrosidase Show Neuroprotective Properties in Cell-Based Models of Alzheimer's Disease," demonstrate in vitro evidence that a STAR compound improves neuronal survival and neurite network and reduces hyperphosphorylated tau in primary rat cortical neurons after Abeta-1-42 injury. Additionally, STAR compounds were shown to reduce hTauO-induced neurotoxicity in primary rat hippocampal neurons. The data therefore demonstrate that structurally targeted allosteric regulators are a potential disease-modifying, novel pharmacological option for the treatment of AD and other tauopathies that warrants further investigation.

08:50 EDT United Health Products reports anomalies from lab testing of HemoStyp samples - United Health Products provided an update on the company's FDA Premarket Approval application process. As disclosed in a press release on January 31, 2023, UHP produced three batch lots of its HemoStyp gauze product to demonstrate consistent manufacturing results, which the company believes to be an important criterion for Premarket Approval. Laboratory testing on samples of these lots was completed to confirm the consistency of the company's manufacturing process, which results are to be included in its final PMA application. The testing results showed several anomalies in product pH level and moisture content that the company, in consultation with the laboratory leadership, believes resulted from unintended partial oxidation during the sample cutting and packaging process that was conducted by an external component supplier. The company notes that this process was carried out to create testing samples and is not an element of the standard manufacturing, packaging and sterilization process that will be reviewed by the FDA in the PMA application. UHP notes further that testing results for other characteristics, such as chloride content, were well below tolerance thresholds in all samples. In light of these anomalies a second round of testing for manufacturing consistency is underway. The company has produced new batch lots which have been delivered directly to the lab where samples will be taken in a more controlled environment. These samples will then undergo the required tests to confirm the uniformity and consistency of the company's manufacturing process. In parallel with this effort, preparation for packaged product testing by the company's packaging partner will continue, providing necessary confirmation of packaging integrity, effective sterilization and other criteria. Because the required tests are being performed by external service providers it is difficult to predict with certainty the time to completion of these final steps in the company's PMA application. Based on recent lab performance and detailed discussions with its packaging partner regarding the necessary protocols to establish packaging procedures that meet the rigorous Class III standards, the company now anticipates it may take until the end of June 2023 to complete, analyze and incorporate these procedures and results into a consolidated PMA application.

08:48 EDT Conduent implements child support payment processing system in New Hampshire - Conduent announced the implementation of an advanced cloud-based system to process child support payments for the New Hampshire Department of Health and Human Services. The new system, which supports more than 31,000 families in New Hampshire, adds automated processes for the department's State Disbursement Unit and makes disbursements more quickly and efficiently. The SDU securely receives and distributes child support payments via various methods like debit cards, electronic deposits or checks.

08:37 EDT Taoping enters long-term strategic cooperation agreement with Zhaoyuan City - Taoping has entered into a long-term strategic cooperation agreement with Zhaoyuan City, Shandong Province. Under the Agreement, Taoping expects to provide customized intelligent product solutions, including its IoT Smart Rest Station, fully autonomous street sweeper, smart large screen displays, and Blue Box off-grid wastewater treatment solution. Zhaoyuan City plans to provide the company with multiple channels of support and preferential policies. As part of the Agreement, both parties will also work together on low-carbon environmental protection, urban renewal, rural ecological revitalization, and other related projects. Zhaoyuan City, located in East China, is an industrial and agricultural city, with more than 500,000 residents.

08:36 EDT CytoSorbents announces study on CytoSorb hemoperfusion - CytoSorbents highlights the recently published study entitled, "CytoSorb hemoperfusion markedly attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo" in the renowned medical journal "Critical Care." In this landmark publication, leading sepsis researchers in the group of Prof. Dr. Peter Pickkers from Radboud University Medical Center, Nijmegen, Netherlands convincingly demonstrate the robust ability of CytoSorb to rapidly reduce cytokine storm during systemic hyperinflammation in a well-controlled and well-established human experimental sepsis model. In this clinical study, Jensen, et al., intravenously administered bacterial lipopolysaccharide endotoxin - a dangerous toxin found on the surface of most Gram-negative bacteria such as E. coli, Pseudomonas, and Klebsiella - to twenty-four healthy male volunteers. Endotoxin is a common culprit in sepsis that potently activates the immune system, triggering the high production of cytokines, often called a "cytokine storm," and severe inflammation. Extracorporeal blood purification with CytoSorb was then used to treat half of the volunteers for a total of 6 hours. Baseline demographic characteristics between those that received CytoSorb therapy and those that did not were similar. All other interventions between the two groups were identical. Cytokine measurements were taken every hour or half-hour throughout the experiment. Intravenous administration of endotoxin resulted in impressive transient increases in cytokine concentrations in the control group, characteristic of levels seen in a true cytokine storm. Meanwhile, the CytoSorb group had significantly lower plasma levels of cytokines, including TNF and MIP-1a, showing that CytoSorb profoundly attenuates the increase in circulating cytokine concentrations during endotoxin-induced systemic inflammation in humans. This result is very clinically relevant, as the severity and duration of cytokine storm and inflammation in sepsis are directly correlated with life-threatening complications such as shock, respiratory failure, and other organ failure, and the risk of death.

08:34 EDT Global Tech Industries updates shareholders on contact with FINRA - Global Tech Industries has been in further contact with FINRA regarding its corporate action request to issue a dividend to its shareholders, in the form of one restricted share for every ten shares held, as of the record date of April 15, 2023. Since its board of directors initially approved and authorized management to submit the corporate action request on March 9, 2023, FINRA has asked for additional information and clarification regarding the dividend request, which the company promptly supplied. The Company is focused on complying with any and all requests from FINRA in order to complete the dividend for its shareholders and is not undertaking, nor has plans to undertake any other corporate actions, including a forward or reverse split of its common stock.

08:34 EDT KULR Technology appoints Shawn Canter as new FO - KULR Technology (KULR) announced it has strengthened its executive leadership team with the appointment of Shawn Canter as its Chief Financial Officer, CFO. Canter begins his role at the Company effective March 31, 2023.Canter is a seasoned corporate executive and board member with over 25 years of experience leading teams in hands-on roles in both institutional and early/growth stage companies bringing solutions to complex situations. He gained significant financial and transactional experience as an executive in M&A at Goldman Sachs (GS) and at Bank of America's investment bank where he also served as Chief Operating Officer of M&A.

08:33 EDT CVS Health completes acquisition of Signify Health - Under the terms of the transaction, each outstanding share of Signify Health (SGFY) common stock is being exchanged for $30.50 in cash, representing a total transaction value of approximately $8B. CVS Health (CVS) funded the transaction price with existing cash and available resources and is committed to maintaining its current credit ratings.

08:31 EDT VirnetX enters non-exclusive sales agreement with Solution Synergy - VirnetX announced that it has entered into a non-exclusive sales agreement with Solution Synergy, under which Solution Synergy will market and sell the VirnetX One family of products, including VirnetX Matrix and War Room, to healthcare enterprises as well as state and local governments and public safety departments.

08:20 EDT Achieve Life says last subject's last visit complete for Phase 3 ORCA-3 trial - Achieve Life Sciences announced that the last study follow-up visit for the last subject enrolled in the Phase 3 ORCA-3 trial has occurred. "We are pleased to have reached this final milestone in the Phase 3 ORCA-3 trial and continue to expect topline data results from this trial, as well as results from the ORCA-V1 trial of cytisinicline as a treatment for e-cigarette cessation, to be reported in the second quarter of this year," commented John Bencich, Chief Executive Officer of Achieve. The ORCA-3 trial randomized 792 subjects across 20 clinical locations in the United States.

08:19 EDT BioCardia sees cash runway into 3Q23 - Net cash used in operations was approximately $10.6 million in 2022, compared to $10.4 million in 2021. The Company ended the year with cash and cash equivalents totaling $7.4 million, providing runway into the third quarter of 2023.

08:17 EDT Verses, SimWell partner to enhance digital twin stimulations with KOSMOS - VERSES Technologies announces a strategic partnership with SimWell. This collaboration strives to leverage the power of knowledge models and digital twin technologies to deliver insights, optimization, and efficiency for businesses worldwide. The partnership is expected to leverage VERSES' advanced A.I. and SimWell's experience building digital twins to deliver predictive modeling simulations. This collaboration aims to empower enterprise clients in the retail, warehousing, consumer brand, manufacturing, logistics, and supply chain sectors to generate real-time models to make data-driven decisions, optimize processes, and reduce costs while setting themselves apart in the competitive global market. "Spending $500K-$1M simulating your process before committing to multimillion dollar and multi-year projects only works if you trust the simulation and with SimWell that trust has been demonstrated repeatedly around the world." said James Hendrickson, President and General Manager of VERSES Logistics Inc., a wholly owned subsidiary of the Company that serves as its global enterprise-specific business unit. "We're most excited about the cultural and technical alignment between VERSES and SimWell. Our combined energy benefits global customers and partners with expertise and tools that drive transformation across enterprise verticals."

08:15 EDT G Medical Innovations enters into agreement with AdventHealth Central Florida - G Medical Innovations announced that its wholly-owned subsidiary, G Medical Innovations USA, Inc., has entered into an agreement with AdventHealth Central Florida to expand the health care system's remote patient monitoring capabilities. Pursuant to the agreement, G Medical Innovations will provide devices to AdventHealth for remote patient monitoring, mobile cardiac telemetry and extended holter monitoring for AdventHealth patients. The innovative technology provided by G Medical Innovations will help providers better monitor and diagnose new onset cardiovascular symptoms as part of AdventHealth's growing virtual care center. Available to both adult and pediatric patients in AdventHealth's Central Florida division, that sees more than 5.7 million patients annually, the cloud-based monitoring system includes a small, waterproof monitor received by mail after discharge from one of AdventHealth's 20 hospitals and emergency departments in Central Florida. Patient symptoms can then be monitored in real-time from the comfort of their home through the AdventHealth virtual care center. Those who experience unusual arrythmias or other monitored symptoms receive immediate communication from providers, enabling greater access to care and, in some cases, earlier diagnoses of serious medical conditions.

08:13 EDT First Solar announces facility in India awarded financial incentives - First Solar announced that its manufacturing facility in India has been awarded financial incentives under the Indian government's Production Linked Incentive program. First Solar was one of only three manufacturers selected to receive the full range of incentives, which are reserved for fully vertically integrated manufacturing. The incentives are subject to the facility meeting product efficiency and domestic value creation thresholds, which will be evaluated on a quarterly basis beginning in the second quarter of 2026 through 2031. First Solar's new facility, expected to be commissioned in the second half of this year, is located in the state of Tamil Nadu and will have an annual nameplate capacity of 3.4 gigawattsDC. First Solar is also expanding its US manufacturing footprint, which currently stands at over 5 GW of annual nameplate capacity with three operating factories in Ohio, to over 10 GW by 2025 when it completes its new $1.1 billion factory in Alabama and a $185 million expansion of its existing capacity in Ohio. The company is expected to have over 20 GW of annual global nameplate manufacturing capacity by 2025.

08:12 EDT Enphase Energy launches new IQ8 microinverters in France, the Netherlands - Enphase Energy announced that it has started shipping IQ8 Microinverters, with peak output AC power of 384VA, in France and the Netherlands to support newer high-powered solar modules. This follows the introduction of IQ8M and IQ8+ Microinverters last year in these markets. The new IQ8 Microinverters are designed to maximize energy production and can manage a continuous DC current of 14 amperes, supporting higher powered solar modules through increased energy harvesting, while maintaining full compatibility with previously released IQ8 Microinverters. "We are excited to continue growing and innovating with leading installers across Europe to meet the increasing customer demand for clean, reliable energy," said Dave Ranhoff, chief commercial officer at Enphase Energy. "Our latest IQ8 products give our installers an edge to help maximize the value of home energy management systems and provide the best customer experience possible."

08:10 EDT Kala Pharmaceuticals appoints Francis Mah as chief medical advisor - Kala Pharmaceuticals announced the appointment of Francis Mah, M.D., as Chief Medical Advisor. In this newly established role, Dr. Mah will provide support for Kala's clinical development and medical activities and will play a key role in interactions with eye care professionals. Dr. Mah will serve in this role on a part time basis while continuing his ongoing position as Director of Cornea and External Disease and the Co-Director, Refractive Surgery at Scripps Clinic.

08:09 EDT DoubleDown announces results of 2023 Annual General Meeting - DoubleDown Interactive announced that at the annual general meeting of shareholders held on March 29, 2023 at 11:00 a.m., Korea Standard Time in Seoul, Korea, the following actions were taken by the shareholders of record as of December 31, 2022 on the proposed resolutions: Approval of the 15th financial statements for the fiscal year ended December 31, 2022; Rejection of the shareholder proposal for a declaration of a cash dividend in the aggregate amount of $50,000,000 as proposed by STIC Special Situation Diamond Limited; Approval of the amendment to business purposes of the Company under Chapter I, Article 2 of the Company's Articles of Incorporation; Re-election of each of Yanghoon Cho and Jaesung Chung as a non-executive independent director of the Company for a new three-year term commencing on May 20, 2023 and ending on May 20, 2026; Approval of the aggregate remuneration limit of KRW5,000,000,000 for independent directors and executive officers for the fiscal year ending December 31, 2023; and Ratification of the appointment of Samil PricewaterhouseCoopers as the independent registered public accounting firm of the Company for the fiscal years ending December 31, 2023, 2024 and 2025.

08:08 EDT Rapt Therapeutics announces initiation of Phase 2a trial of RPT193 - RAPT Therapeutics announced that it has initiated its global 14-week randomized, double-blind, placebo-controlled Phase 2a clinical trial to evaluate the efficacy and safety of RPT193 as an oral, once-daily monotherapy in patients with moderate-to-severe asthma. "We are excited by the potential of RPT193 as a well-tolerated, once-daily, oral treatment for patients with asthma," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "Following promising results from our Phase 1b trial in atopic dermatitis, where RPT193 demonstrated clinically meaningful improvement in signs and symptoms of the disease, we see asthma as the next pillar in our pipeline-in-a-product strategy. We look forward to generating proof-of-concept in this indication."

08:07 EDT Baltimore Orioles select Shift4 to process payments for ballpark concessions - "We're thrilled to partner with the Orioles to deliver a best-in-class guest experience," said Anthony Perez, Shift4's SVP of New Verticals. "Fans can expect all their transactions at concession stands and retail locations to be as quick and seamless as possible so that they can get back to enjoying the game." Today, Shift4's integrated commerce solutions are used by every major professional sports league as well as colleges, entertainment venues, and many other business verticals - transforming the way fans and guests shop, order, and pay. To learn more, visit shift4.com/sports-entertainment.

08:06 EDT Third Harmonic Bio expects cash to fund requirements through next 12 months - Cash and cash equivalents totaled $288.9 million as of December 31, 2022. Based on the company's current operating plan, Third Harmonic Bio believes that its existing cash and cash equivalents, will be sufficient to fund its operating expenses and capital expenditure requirements through at least the next twelve months.

08:06 EDT EzFill and SaverOne 2014 launch driving safety pilot program in Florida - EzFill (EZFL) announced a new pilot program with SaverOne 2014 (SVRE). SaverOne has technology which prevents driver distraction caused by cell phones, by preventing a driver's access to various apps on the device while allowing other passengers to use their devices normally. In its first pilot trial in the United States, SaverOne has provided its technology and service to EzFill, equipping a number of EzFill's mobile fueling trucks with the SaverOne technology. The goal of the trial is to reduce distractions from cell phone use by EzFill drivers, ultimately aiming to reduce the chances of a costly fuel truck accident.

08:04 EDT Honeywell invests in Energy-as-a-Service provider Redaptive - Honeywell announced a strategic investment in Redaptive, which will accelerate a collaboration to bring Energy-as-a-Service capabilities to private sector-owned commercial and industrial buildings. This investment helps enable the deployment of technologies designed to reduce carbon emissions across a portfolio of buildings. Terms of the investment were not disclosed. This collaboration aims to create the opportunity for customers to generate energy savings in a capital efficient manner.

08:02 EDT Spire CEO Suzanne Sitherwood retiring at year's end, board initiates CEO search - Spire CEO Suzanne Sitherwood has informed the Board of her intention to retire from the company at the end of 2023, after serving 12 years in the role. The Board has initiated a search process to find a successor. The Board will engage a leading, independent executive search firm to assist in a thorough and comprehensive process that considers both internal and external candidates.

07:40 EDT PharmaTher provides update on FDA Type C Meeting for KETARX in LID-PD - PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced an update on the Type C meeting with the U.S. Food and Drug Administration ("FDA") for advancing KETARX(TM) (ketamine) towards Phase 3 clinical development as a treatment for levodopa-induced dyskinesia in Parkinson's disease. The FDA supported the Company's overall approach for the LID-PD program and offered the following feedback: Agreed that with the appropriate data, a new drug submission would be considered under the 505(b)(2) regulatory pathway; Confirmed that a single confirmatory trial can be the basis for marketing approval under specific circumstances, including treatment duration and final study results; Guided on treatment duration, use of evaluation scales and selection of endpoints to ensure treatment approach aligns with expectations for a chronic condition; Provided information to enhance the safety monitoring to ensure potential physical and cognitive performance issues can be minimized, adverse events do not go unnoticed, and strategies to minimize patient risk; Identified the need for certain short-term non-clinical studies to support increased treatment duration; and Advised the Company to make a formal submission to be considered for Fast Track designation. The Company plans to adapt its proposed clinical development program to align with the FDA's recommendations and the Company's resources towards study evaluations leading into a Phase 3 clinical study and a potential FDA approval via the 505(b)(2) regulatory pathway. The Company will provide updates to its clinical development initiatives as they arise.

07:38 EDT DraftKings launches DK Horse app - DraftKings (DKNG) announced that DK Horse, the digital gaming operator's first-ever horse racing product, has launched in twelve states and expects to launch in additional states by the Kentucky Derby on Saturday, May 6, 2023. The standalone, DK Horse-branded app allows eligible customers to access pari-mutuel wagering on horse racing. In November 2022, DraftKings and Churchill Downs Incorporated (CHDN) announced a multi-year agreement pursuant to which CDI's subsidiary, TwinSpires, agreed to power the advance deposit pari-mutuel wagering technology for DK Horse.

07:34 EDT Major Drilling appoints Caroline Donally to board of directors - Major Drilling Group announced the appointment of Caroline Donally to the Company's Board of Directors effective April 1, 2023. She is currently the Managing Partner of Sprott Resource Streaming and Royalty Corp.

07:20 EDT Nano Dimension increases offer to acquire Stratasys to $19.55 per share - Nano Dimension (NNDM) has submitted a revised offer to acquire Stratasys Ltd. (SSYS) for $19.55 per share in cash. Under the terms of the Improved Proposal, Nano Dimension would acquire the remaining shares of Stratasys it does not currently own for an aggregate of approximately $1.2 billion on a fully diluted basis. This offer represents a premium of 37% to the closing trading price as of March 3rd, 2023, a 40% premium to the Company's 30-day VWAP, 51% premium to the 60-day VWAP and a 47% premium to the 90-day VWAP as of March 3rd, 2023. Nano Dimension has been the largest shareholder of Stratasys since July 2022 and currently owns approximately 14.5% of Stratasys' outstanding shares. The company said, "Nano Dimension's Improved Proposal represents a significant increase in value of $1.55 per share, or 9%, as compared to its March 6th, 2023, proposal and offers compelling and certain value to Stratasys shareholders at a time of ongoing market volatility."

07:18 EDT Innovative Industrial Properties names David Smith CFO, Hastings as COO - Innovative Industrial Properties announced the hiring of David Smith as Chief Financial Officer and Treasurer, and the promotions of Catherine Hastings to Chief Operating Officer and Ben Regin to Chief Investment Officer. Smith previously served as Executive Vice President and Chief Financial Officer of Aventine Property Group, , a privately-held real estate investment trust focused on the regulated cannabis industry, since Aventine's spin-off from Treehouse Real Estate Investment Trust in January 2021.

07:14 EDT Pieris Pharmaceuticals expects cash to fund operations for over 12 months - Cash, cash equivalents, and investments totaled $59.2 million for the year ended December 31, 2022, compared to a cash and cash equivalents balance of $117.8 million for the year ended December 31, 2021. The decrease was due to funding operations in 2022. The Company believes operations are sufficiently funded for more than the next 12 months.

07:11 EDT Biosynex extends tender offer for shares of Chembio Diagnostics - Biosynex announced that Project Merci Merger Sub, a Nevada corporation and its wholly-owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock of Chembio Diagnostics at a price of $0.45 per Share, net to the seller in cash, without interest and subject to any required tax withholding, until 6:00 p.m., New York City time on April 12, 2023, unless further extended. The tender offer was previously scheduled to expire at 6:00 p.m., New York City time, on March 28, 2023. All other terms and conditions of the tender offer remain unchanged. Securities Transfer Corporation, the depositary and paying agent for the tender offer, has indicated that, as of 6:00 p.m., New York City time, on March 28, 2023, approximately 14,137,808 Shares had been validly tendered into and not validly withdrawn from the tender offer, representing approximately 38.5% of the Shares then outstanding. Stockholders who have already tendered their Shares into the tender offer do not have to re-tender their Shares or take any other action as a result of the extension of the expiration time of the tender offer. Completion of the tender offer remains subject to additional conditions described in the Tender Offer Statement on Schedule TO filed by Purchaser and Biosynex with the U.S. Securities and Exchange Commission on February 14, 2023.

07:10 EDT Lithium Ionic reports assay results from hole at Bandeira property - Lithium Ionic reports assay results from hole ITDD-23-065 drilled at its 100%-owned Bandeira property as part of an ongoing 30,000 metre drill program at the Itinga Project, located within the Aracuai district in the state of Minas Gerais, Brazil. ITDD-23-065 represents the best hole drilled to date at Bandeira, intersecting 13 well-mineralized individual pegmatite veins with high grade lithium content over widths of up to 24 metres. The Company has completed 22,000 metres of the drill program to date between the Bandeira and Galvani properties, which together cover only 872 of the 14,182 hectares it controls in this lithium-producing district. Bandeira is located approximately 500 metres south of Companhia Brasileira de Litio's Cachoeira lithium mine, and approximately 700 metres North of Sigma Lithium's large Barreiro lithium deposit. Hole ITDD-23-065 Highlights: Hole drilled to a depth of approximately 500m, intersected 13 individual well-mineralized stacked pegmatite veins from 160m to 485m down hole, consistent with other large lithium deposits nearby. Best intersections drilled to date at Bandeira, with high lithium content over significant widths, including: 1.32% Li20 over 24m, incl. 2.12% Li2O over 8m; 2.53% Li20 over 6.09m; 1.88% Li20 over 7.72m.The hole successfully extended high-grade mineralization a further 200 metres down dip from previously reported hole ITDD-23-52, exceeding expectations with a continuous mineralized zone extending 500m from surface which significantly widens at depth. Two 150m step-out holes planned to test mineral continuity to the North-West, while assays are pending for drilled holes ITDD-23-060 and ITDD-23-052 to confirm up dip mineral continuity.

07:08 EDT Regeneron announces EC approved Libtayo in combination with chemotherapy - Regeneron Pharmaceuticals announced that the European Commission, EC, approved Libtayo in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer, NSCLC, with greater than or equal to1% PD-L1 expression. This includes patients that have no EGFR, ALK or ROS1 aberrations and whose tumors are metastatic or locally advanced and not candidates for definitive chemoradiation. "Today's approval considerably expands the number of people in Europe with advanced non-small cell lung cancer who are eligible for Libtayo-based first-line treatment, including those with PD-L1 expression ranges most commonly seen in real-world practice," said Israel Lowy, M.D., Ph.D., Senior Vice President, Translational and Clinical Sciences, Oncology at Regeneron. "We are proud that Libtayo continues to distinguish itself among PD-1 pathway blockers, as just one of two PD-1 inhibitors to be approved for use across squamous and non-squamous forms of advanced NSCLC in both combination and monotherapy settings. This marks the fifth approval for Libtayo in Europe."

07:07 EDT Macy's announces CFO Adrian Mitchell to assume COO role as well - As a part of the leadership transition, the company has also announced that Macy's CFO Adrian Mitchell's responsibilities have been expanded to include the role of chief operating officer. In the combined role, Mitchell will lead the stores, technology and supply chain teams, in addition to his existing finance and real estate responsibilities. Gennette will work side-by-side with Spring and Mitchell until February 2024 to ensure a transition.

07:04 EDT Macy's CEO Jeff Gennette to retire, Tony Spring to succeed - Macy's announced that chairman and CEO of Macy's, Jeff Gennette, plans to retire in February 2024 after serving the company for 40 years. Following a succession planning process that included an internal and external search, Tony Spring, Macy's. executive vice president and Bloomingdale's chairman and chief executive officer, has been appointed by the board of directors as Macy's president and CEO-elect, and a member of the board of directors. As president, Spring will be responsible for leading Macy's digital, customer, merchandising, and brand teams, while overseeing Bloomingdale's and bluemercury.

07:03 EDT Matrix Service awarded service EPC for ethane storage tank - Matrix Service Company (MTRX) announced its subsidiary, Matrix Service, has been awarded the greenfield engineering, procurement, and construction of a second 600,000-barrel cryogenic ethane storage tank for a subsidiary of Enterprise Products Partners (EPD) along the Texas Gulf Coast. The project, which was taken into Matrix's backlog in the second quarter of Fiscal 2023, supports a continued demand for ethane in the global marketplace. Engineering for the storage tank will be completed by Matrix PDM Engineering.

06:47 EDT Ault Inc. subsidiary BitNile partners with Core Scientific for Bitcoin mining - Ault Alliance has announced a strategic collaboration between its wholly owned subsidiary, BitNile, and Core Scientific, a provider of high-performance blockchain computing data centers and software solutions. This collaboration will enable BNI to operate 3,000 S19j Pro miners in Core Scientific's existing facilities starting in April. As part of the collaboration, Core Scientific is dedicated to offering BNI its exclusive mining capabilities at its state-of-the-art mining facilities alongside Core Scientific's existing mining fleet. The Bitcoin miners are set to arrive at Core Scientific's facilities as early as this week.

06:35 EDT Teleflex signs supply agreement for staple line reinforcement material - Teleflex announced a supply agreement with W. L. Gore to use Gore's Gore Seamguard Bioabsorbable Staple Line Reinforcement material in a staple line reinforcement device designed by Teleflex for use with the Titan SGS Powered Stapling Device. With these two technologies paired together, bariatric surgeons will be able to utilize the technology of the Titan SGS Device with Gore Seamguard Bioabsorbable Staple Line Reinforcement material. Teleflex will provide specifics around future product commercialization dates. Developed by Standard Bariatrics, now a part of Teleflex, the Titan SGS Device is a sterile, single patient use instrument used for longitudinal transection and resection of the gastric tissue for sleeve gastrectomy pouch creation. The powered stapling Titan SGS Device cuts stapling time for a sleeve gastrectomy in half with one 55-second firing sequence. Gore Seamguard Bioabsorbable Staple Line Reinforcement is a synthetic buttressing material engineered to reduce leaks and bleeding and strengthen the staple line by redistributing the pressure exerted by an individual staple over a wider area.

06:05 EDT Lizhi granted approval for transfer to Nasdaq Capital Market. - Lizhi announced that the Listing Qualifications department of The Nasdaq Stock Market approved the company's request to transfer the listing of the company's ADSs from The Nasdaq Global Market to The Nasdaq Capital Market. The transfer is expected to take effect at the opening of business on March 30. The transfer of the Company's listing to The Nasdaq Capital Market is not expected to have any impact on trading in the company's ADSs. On October 11, 2022, the company received a letter from Nasdaq indicating that the company was not in compliance with Nasdaq Listing Rules, as the closing bid price of the ADSs had been below $1.00 per ADS for the previous 30 consecutive business days. In response, the Company submitted an application to transfer the listing of its ADSs from The Nasdaq Global Market to The Nasdaq Capital Market, and upon transfer, the Company will be afforded the remainder of this compliance period of 180 days. If compliance with the $1.00 bid price requirement cannot be demonstrated by April 10, 2023, the company may be eligible for an additional compliance period if it meets the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement.

06:02 EDT Conn's plans to open 11 new standalone locations in FY24 - The company opened four new standalone stores and closed one standalone store during the fourth quarter of fiscal year 2023 bringing the total store count to 168 in 15 states. During fiscal year 2024, the company plans to open 11 new standalone locations.

05:43 EDT UBS board names Sergio Ermotti as new group CEO, effective April 5 - Further to the announcement regarding UBS's (UBS) acquisition of Credit Suisse (CS), the Board of Directors of UBS have appointed Sergio P. Ermotti as Group CEO and President of the Group Executive Board, effective on 5 April 2023, after the Annual General Meeting. He will succeed Ralph Hamers, who has agreed to step down to serve the interests of the new combination, the Swiss financial sector and the country. Ralph Hamers will remain at UBS and work alongside Sergio P. Ermotti as an advisor during a transition period to ensure a successful closure of the transaction and a smooth hand-over. The Board took the decision in light of the new challenges and priorities facing UBS after the announcement of the acquisition. Ermotti was the Group CEO of UBS for 9 years and repositioned UBS following the severe challenges arising from the Global Financial Crisis, the bank notes. UBS Chairman Colm Kelleher said: "Ralph has been an outstanding CEO of UBS, driving the group to unprecedented success despite a challenging environment. Under his leadership UBS built the strengths that have put us in a position to stabilize Credit Suisse and ensure a successful integration." Reference Link

05:22 EDT OKYO Pharma chairman purchases 12,500 ADS for $1.32 - OKYO Pharma announces that it has been notified that Panetta Partners, an entity in which Gabriele Cerrone, the executive chairman has a beneficial interest, purchased 12,500 of the company's ADSs on Nasdaq at a price of $1.32 per ADS.